Boditech Med Inc. (KOSDAQ:206640)

Market Cap	222.78B -37.3%
Revenue (ttm)	162.09B +17.3%
Net Income	23.65B -13.2%
EPS	1,091.00 -12.2%
Shares Out	20.34M
PE Ratio	10.04
Forward PE	n/a
Dividend	150.00 (1.36%)
Ex-Dividend Date	Mar 31, 2026

Volume	67,405
Average Volume	50,259
Open	11,020
Previous Close	10,950
Day's Range	10,720 - 11,150
52-Week Range	10,370 - 17,280
Beta	n/a
RSI	40.08
Earnings Date	May 26, 2026

About Boditech Med

Boditech Med Inc. develops products for in-vitro diagnostics and diagnostic reagents. It offers ichroma II, an automatic or semiautomatic in-vitro diagnostic device that measures the concentration of analytes, contained in blood, urine, or other samples, in quantitative, or semi-quantitative ways; automated fluorescent immunoassay systems under AFIAS-6 and AFIAS-1 names that uses blood, urine, and other samples to measure quantitatively or semi-quantitatively the concentration of targeted analytes; ichroma-50, an automatic immunoassay analyzer ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1998
• Country: South Korea
• Stock Exchange: KOSDAQ
• Ticker Symbol: 206640

Financial Performance

In 2025, Boditech Med's revenue was 162.09 billion, an increase of 17.32% compared to the previous year's 138.16 billion. Earnings were 23.65 billion, a decrease of -13.23%.